| 孙燕,赵清霞,李超锋,杨萱,张雪,刘春礼,陈昭云.河南省2003-2005年HIV/AIDS抗病毒治疗随访10年生存状况分析[J].中华流行病学杂志,2018,39(7):966-970 |
| 河南省2003-2005年HIV/AIDS抗病毒治疗随访10年生存状况分析 |
| Analysis on 10 year survival of HIV/AIDS patients receiving antiretroviral therapy during 2003-2005 in Henan province |
| 收稿日期:2017-12-26 出版日期:2018-07-17 |
| DOI：10.3760/cma.j.issn.0254-6450.2018.07.019 |
| 中文关键词: 艾滋病 抗病毒治疗 生存分析 长期 影响因素 |
| 英文关键词: HIV/AIDS Antiretroviral therapy Survival analysis Long-term Influencing factors |
| 基金项目:国家科技重大专项（2012ZX10001-003-001）；河南省科技攻关计划项目（162102310217） |
|
| 摘要点击次数: 2866 |
| 全文下载次数: 1317 |
| 中文摘要: |
| 目的 分析河南省艾滋病感染者和艾滋病患者（HIV/AIDS）抗病毒治疗（antiretroviral therapy，ART）10年生存状况及影响长期生存的因素。方法 利用国家艾滋病抗病毒治疗数据库，收集河南省2003－2005年接受ART的HIV/AIDS基本情况和治疗随访信息，采用寿命表法和Cox比例风险模型分析生存状况和影响长期生存的危险因素，采用SPSS 23.0软件进行统计分析。结果 2003－2005年开始ART的2 448例HIV/AIDS中，男性占53.5%（1 309/2 448），女性占46.5%（1 139/2 448），40～59岁占70.1%（1 715/2 448），以血液传播为主，占95.5%（2 337/2 448）；ART后随访10年，死于艾滋病及相关疾病719例，死亡率为3.78/100人年（719/19 010人年）；患者第1、3、5、10年累计生存率为0.94、0.86、0.78、0.69。相对于年龄<40岁组，40～、50～、60～和≥70岁组HR值（95% CI）分别为1.417（0.903～2.222）、1.834（1.174～2.866）、2.422（1.539～3.810）和3.424（2.053～5.709）；相对于基线CD4+T淋巴细胞（CD4）>350个/μl，CD4<50、50～199、200～350个/μl的HR值（95% CI）值分别为7.105（5.449～9.264）、4.175（3.249～5.366）和2.214（1.691～2.900）；男性相对于女性HR=1.480（95% CI：1.273～1.172）、没有更换二线治疗HR=11.923（95% CI：9.410～15.104）。结论 河南省早期HIV/AIDS接受ART 10年后的累计生存率为0.69，男性、年龄较大、基线CD4水平低、未及时更换二线抗病毒药物为影响其长期生存的危险因素。 |
| 英文摘要: |
| Objective To understand the survival of HIV/AIDS patients after receiving antiretroviral therapy for 10 year in Henan province and related factors. Methods The database of national integrated management system of HIV/AIDS was used to collect the basic information and follow-up information of HIV/AIDS patients who received antiretroviral therapy between 2003 and 2005 in Henan province. Software SPSS 23.0 was used to analyze the patients' survival and related factors based on the life-table method and Cox proportional hazards model. Results Among the 2 448 HIV/AIDS patients who started antiretroviral therapy during 2003-2005, the men accounted for 53.5%, and women accounted for 46.5%. Up to 70.1% of the patients were aged 40-59 years and 95.5% of the patients had blood borne infections. The patients were observed for 10 years after antiviral treatment, and 719 cases died from AIDS related diseases, with a mortality rate of 3.78/100 per year (719/19 010 per year). The cumulative survival rates of patients within 1-year, 3 years, 5 years and 10 years were 0.94, 0.86, 0.78, 0.69 respectively. Compared with the patients aged <40 years, the HRs of the patients aged 40-, 50-, 60-and ≥ 70 years were 1.417 (95%CI:0.903-2.222), 1.834 (95%CI:1.174-2.866), 2.422 (95%CI:1.539-3.810) and 3.424 (95%CI:2.053-5.709) respectively. Compared with patients with baseline CD4+T lymphocyte >350 unit/ul, the HRs of the patients with CD4+T lymphocyte <50 unit/μl, 50-199 unit/ul and 200-350 unit/ul were 7.105 (95%CI:5.449-9.264), 4.175 (95%CI:3.249-5.366) and 2.214 (95%CI:1.691-2.900) respectively. Compared with the women, the HR of the men was 1.480 (95%CI:1.273-1.172). Compared with the patients who received second line ART therapy, the HR of patients receiving no second line therapy was 11.923 (95%CI:9.410-15.104). Conclusions The cumulative survival rate the HIV/AIDS patients after 10 years of antiretroviral therapy reached 0.69 in Henan. Male, old age, low basic CD4+T lymphocyte count and receiving no second line therapy were the risk factors for long-term survival of AIDS patients. |
|
查看全文
Html全文
查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
